Cargando…
Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis
BACKGROUND: Oral sodium zirconium cyclosilicate (SZC) is a novel potassium binder capable of achieving a rapid reduction of serum potassium (sK(+)) and maintaining a long-term normokalemia. We undertook a meta-analysis to summarize and evaluate the effects surrounding SZC in patients with hyperkalem...
Autores principales: | Zhang, Yaru, Xu, Ruiling, Wang, Fanghao, Liu, Youxia, Xu, Junying, Zhao, Na, Cheng, Fajuan, Long, Lihong, Jia, Junya, Lin, Shan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452568/ https://www.ncbi.nlm.nih.gov/pubmed/33459923 http://dx.doi.org/10.1007/s10557-020-07134-2 |
Ejemplares similares
-
Letter to the editor regarding ‘‘Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-analysis: Patiromer and Sodium Zirconium Cyclosilicate in Hyperkalemia’
por: Zarzuela, Donna, et al.
Publicado: (2021) -
Effectiveness of Sodium Zirconium Cyclosilicate in Hemodialysis Patients With Severe Hyperkalemia
por: Ford, Martin, et al.
Publicado: (2021) -
Management of hyperkalemia in chronic heart failure using sodium zirconium cyclosilicate
por: Oshima, Akira, et al.
Publicado: (2021) -
Impact of Sodium Zirconium Cyclosilicate Therapy on Nutrition Status in Patients with Hyperkalemia
por: Imamura, Teruhiko, et al.
Publicado: (2022) -
Risk Factors for Rapid Recurrence of Hyperkalemia following Cessation of Sodium Zirconium Cyclosilicate
por: Imamura, Teruhiko, et al.
Publicado: (2022)